Related Experiment Video

Updated: Jul 15, 2025

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.1K

Systemic under treatment of heart disease in patients with Duchenne muscular dystrophy

Peter Karachunski1, DeWayne Townsend2

  • 1Paul and Sheila Wellstone Muscular Dystrophy Center, University of Minnesota Medical School, Minneapolis, MN, USA; Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.

Neuromuscular Disorders : NMD
|September 29, 2023
PubMed

Insights

Duchenne muscular dystrophy patients are starting heart treatments younger, but 64% still miss recommended cardiac therapies. Improving adherence to cardiac guidelines is crucial for managing dystrophic cardiomyopathy.

Area of Science:

  • Cardiology
  • Neurology
  • Genetics

Background:

  • Duchenne muscular dystrophy (DMD) invariably leads to progressive cardiomyopathy.
  • Cardiac dysfunction is nearly universal in DMD patients, often appearing before age 10.
  • Current guidelines recommend prophylactic cardiac treatment initiation at age 10 for DMD patients.

Purpose of the Study:

  • To evaluate current treatment practices for dystrophic cardiomyopathy in DMD patients.
  • To assess changes in cardiac disease management following updated clinical guidelines.
  • To identify gaps in guideline adherence for cardiac therapies in DMD.

Main Methods:

  • Analysis of clinical data from the Muscular Dystrophy Association.
  • Comparison of treatment initiation ages before and after guideline updates.
  • Assessment of the prevalence of recommended cardiac therapy use in DMD patients.

Main Results:

  • DMD patients are initiating cardiac-directed therapy at significantly younger ages post-guideline issuance.
  • Despite younger initiation, 64% of DMD individuals are not receiving recommended cardiac therapies.
  • A significant gap exists between guideline recommendations and actual clinical practice.

Conclusions:

  • Recent guidelines have influenced earlier initiation of cardiac therapy in DMD.
  • Suboptimal adherence to cardiac treatment guidelines remains a critical issue in managing dystrophic cardiomyopathy.
  • Addressing the adherence gap presents a major opportunity to improve clinical outcomes for DMD patients.

Keywords:
Clinical managementDuchenne muscular dystrophyDystrophic cardiomyopathy

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

32.6K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.4K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K